Trial Profile
A restrospective study to assess patterns and outcomes of ranibizumab dosing regimen in patients with age-related macular degeneration
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 05 Nov 2016
Price :
$35
*
At a glance
- Drugs Ranibizumab (Primary)
- Indications Age-related macular degeneration
- Focus Adverse reactions; Therapeutic Use
- 05 Nov 2016 New trial record